Why are weight-loss drugs now heart drugs too?

Heart failure with preserved ejection fraction (HFpEF) remains a complex and challenging condition, often exacerbated by comorbidities like obesity and hypertension. Managing these patients requires a comprehensive approach, but the direct impact of weight-loss interventions on cardiovascular outcomes, particularly in HFpEF, has been a subject of ongoing investigation. The field has moved beyond simply observing weight reduction, now demanding evidence of improved hard clinical endpoints and patient-reported outcomes.³

A systematic review and network meta-analysis published in BMJ in 2026, conducted by Nong, Shi, and Xie, aimed to synthesize the comparative benefits and harms of various anti-obesity drugs for adults with overweight or obesity.¹ This extensive analysis included data from multiple trials, comparing agents such as semaglutide, tirzepatide, liraglutide, and naltrexone-bupropion against placebo or other active comparators. The researchers sought to provide a definitive evidence summary for policymakers, payers, clinicians, and patients, focusing on both efficacy and safety profiles across a broad spectrum of outcomes, including weight loss, cardiovascular events, and quality of life metrics.¹

What the trials actually measured

The BMJ systematic review encompassed a wide array of studies, drawing data from randomized controlled trials that evaluated pharmacological interventions for weight management.¹ The primary outcome of interest was body weight reduction, but the analysis also delved into secondary outcomes such as changes in blood pressure, lipid profiles, glycemic control, and, crucially, major adverse cardiovascular events (MACE). Quality of life was assessed using validated questionnaires, providing a patient-centric perspective on the benefits of these therapies. The inclusion criteria were broad, covering adults with a body mass index (BMI) of 27 kg/m² or higher with at least one weight-related comorbidity, or a BMI of 30 kg/m² or higher without comorbidities.¹

The comparative effects analysis by Nong, Shi, and Xie found that several agents demonstrated significant weight reduction compared to placebo.¹ Tirzepatide, a dual GIP and GLP-1 receptor agonist, consistently showed superior efficacy in reducing body weight. In head-to-head comparisons, tirzepatide led to a mean difference of -5.2% (95% CI, -6.0% to -4.4%) in body weight reduction compared to semaglutide. This translates to a clinically meaningful difference in weight loss, which often correlates with improvements in metabolic parameters. Semaglutide, a GLP-1 receptor agonist, also demonstrated substantial weight loss, with a mean reduction of -10.5% (95% CI, -11.2% to -9.8%) compared to placebo. Liraglutide, another GLP-1 agonist, showed a more modest but still significant reduction of -5.4% (95% CI, -6.1% to -4.7%) versus placebo.¹

Beyond weight loss, the cardiovascular benefits of these agents were a critical focus. The network meta-analysis indicated that GLP-1 receptor agonists, including semaglutide and liraglutide, significantly reduced the risk of MACE in patients with established cardiovascular disease or multiple risk factors.¹ While specific hazard ratios were not detailed for all comparisons in the abstract, the overall trend pointed towards a protective cardiovascular effect. For instance, semaglutide demonstrated a reduction in MACE, consistent with prior dedicated cardiovascular outcomes trials. Tirzepatide's cardiovascular benefits, while not fully elucidated in this specific abstract, are anticipated given its superior weight loss and glycemic control.¹

Quality of life improvements were also a consistent finding across the more effective weight-loss agents. Patients receiving tirzepatide and semaglutide reported significant enhancements in physical function, self-esteem, and overall well-being, as measured by various patient-reported outcome instruments.¹ These improvements are not merely secondary to weight loss; they reflect a broader impact on daily living and mental health, which is crucial for long-term adherence and patient satisfaction. The data indicated that patients experienced fewer weight-related physical limitations and reported higher satisfaction with their appearance and health status.¹

But, the cost-effectiveness of these newer agents remains a significant consideration for healthcare systems and patients. Johansson, Wilding, and Upadhyay's study, published in the Journal of Medical Economics in 2026, specifically addressed the cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US.² This analysis leveraged data from the SURMOUNT-5 head-to-head phase 3 trial, providing real-world economic implications for these high-efficacy treatments. The study aimed to inform decision-making for payers and health policy makers regarding the optimal allocation of resources for weight management.²

The economic evaluation found that while tirzepatide demonstrated superior clinical efficacy in terms of weight reduction, its cost-effectiveness profile against semaglutide varied depending on specific assumptions regarding long-term cardiovascular benefits and drug pricing.² The SURMOUNT-5 trial data, which formed the basis of this economic model, showed tirzepatide's clear advantage in weight loss. However, the incremental cost-effectiveness ratio (ICER) for tirzepatide versus semaglutide required careful consideration of quality-adjusted life years (QALYs) gained versus the higher acquisition cost. The authors concluded that tirzepatide could be cost-effective under certain willingness-to-pay thresholds, particularly when accounting for its broader metabolic benefits and potential for reducing long-term obesity-related complications.²

Still, the systematic review by Parizad, Hatwal, and Taban Sadeghi in Vascular Health and Risk Management, also published in 2026, provided a broader context on clinical advances in HFpEF, including the role of weight management.³ While not exclusively focused on pharmacological weight loss, this review highlighted the importance of addressing obesity as a modifiable risk factor in HFpEF. It underscored that effective weight reduction strategies, whether pharmacological or lifestyle-based, contribute to improved cardiac function and reduced hospitalizations in this vulnerable patient population. The review emphasized that mechanistic evidence supports the benefits of weight loss in reducing cardiac remodeling, improving diastolic function, and mitigating systemic inflammation, all critical factors in HFpEF pathophysiology.³

The open-label design of some of the trials included in the network meta-analysis is an obvious caveat, potentially introducing bias in patient-reported outcomes. While objective measures like weight change and MACE are less susceptible to such bias, subjective assessments of quality of life could be influenced by patient and clinician awareness of treatment assignment. The duration of follow-up in some studies was also limited, making it challenging to fully ascertain the very long-term cardiovascular benefits and safety profiles of these agents. Long-term data, extending beyond two to three years, are crucial for understanding the true impact on chronic conditions like obesity and cardiovascular disease.¹

Another limitation arises from the heterogeneity of patient populations across the included trials. While the systematic review attempted to standardize inclusion criteria, variations in baseline BMI, presence of comorbidities, and ethnic backgrounds could influence the generalizability of the findings. For instance, a drug tested primarily in a population with established cardiovascular disease might show different benefits than one tested in a population with obesity but no overt cardiovascular disease. The network meta-analysis methodology helps to account for indirect comparisons, but direct head-to-head trials remain the gold standard for definitive comparative efficacy.¹

The cost-effectiveness analysis, while robust, relied on modeling assumptions for long-term outcomes and drug pricing, which can fluctuate.² The actual cost-effectiveness in real-world clinical practice may vary depending on insurance coverage, patient adherence, and the prevalence of comorbidities. Furthermore, the study was specific to the US healthcare system, and its findings may not directly translate to other healthcare environments with different pricing structures and reimbursement policies. The broader implications for global health systems require further localized economic evaluations.²

The trials were not powered to detect differences in rare adverse events, and that gap matters. While common side effects like gastrointestinal disturbances were well-documented, the incidence of less frequent but serious adverse events requires larger, longer-term observational studies or post-marketing surveillance. The long-term safety profile, particularly for newer agents, continues to evolve as more patients receive these treatments. This ongoing monitoring is essential for a complete understanding of the risk-benefit balance.¹

The current evidence, while compelling, does not fully address the optimal sequencing or combination of these therapies, especially for patients who do not achieve sufficient weight loss with a single agent. Future research needs to explore personalized treatment approaches, identifying biomarkers or clinical characteristics that predict response to specific anti-obesity medications. This would allow clinicians to tailor therapy more effectively, maximizing benefits and minimizing trial-and-error prescribing.¹